T
Thomas L. Rudge
Researcher at Battelle Memorial Institute
Publications - 27
Citations - 590
Thomas L. Rudge is an academic researcher from Battelle Memorial Institute. The author has contributed to research in topics: Anthrax Vaccine Adsorbed & Vaccination. The author has an hindex of 12, co-authored 24 publications receiving 525 citations. Previous affiliations of Thomas L. Rudge include Ohio State University & National Center for Immunization and Respiratory Diseases.
Papers
More filters
Journal ArticleDOI
Preferential expression of matrix metalloproteinase-9 in mouse skin after sulfur mustard exposure.
Michael P. Shakarjian,Pinaki Bhatt,Marion K. Gordon,Yoke-Chen Chang,Stacy L. Casbohm,Thomas L. Rudge,Robyn C. Kiser,Carol L. K. Sabourin,Robert P. Casillas,Pamela Ohman-Strickland,David J. Riley,Donald R. Gerecke +11 more
TL;DR: Observations suggest the differential expression of MMP‐2 and ‐9 during the cutaneous response to SM injury and suggest a role for M MP‐9 in SM‐induced injury.
Journal ArticleDOI
Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression.
Christina M. H. Powell,Christina M. H. Powell,Thomas L. Rudge,Quan Zhu,Lee F. Johnson,Ulla Hansen,Ulla Hansen +6 more
TL;DR: LSFdn is a novel regulatory factor that supports progression through S‐phase by targeting a single gene that is critical for cell survival by binding to sites within the TS promoter and intronic regions that are required for this induction.
Journal ArticleDOI
Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers
Robert J. Hopkins,Nancy F. Daczkowski,Paulina E. Kaptur,Derek Muse,Eric Sheldon,Craig LaForce,Suha Sari,Thomas L. Rudge,Edward Bernton +8 more
TL;DR: F Frequencies of injection site and systemic reactions recorded by subjects in diaries for 7 days after each injection were highest with AV7909 Formulation 1, and further studies of doses and dosing regimens are planned to assess the immunogenicity and reactogenicity of AV79 09.
Journal ArticleDOI
Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.
Boris Ionin,Robert J. Hopkins,Brett Pleune,Gloria S. Sivko,Frances M. Reid,Kristin H. Clement,Thomas L. Rudge,Gregory V. Stark,Alison Innes,Suha Sari,Tina Guina,Cris Howard,Jeffrey G. Smith,M. Lisa Swoboda,Ekaterina Vert-Wong,Virginia Johnson,Gary S. Nabors,Mario H. Skiadopoulos +17 more
TL;DR: The animal data provide initial information on protective antibody levels for anthrax, as well as support previous findings regarding the ability of AVA to provide added protection to B. anthracis-infected animals compared to antimicrobial treatment alone.
Journal ArticleDOI
Murine Cytomegalovirus Stimulates Cellular Thymidylate Synthase Gene Expression in Quiescent Cells and Requires the Enzyme for Replication
Giorgio Gribaudo,Ludovica Riera,David Lembo,Marco De Andrea,Marisa Gariglio,Thomas L. Rudge,Lee F. Johnson,Santo Landolfo +7 more
TL;DR: It is shown that murine CMV infection of quiescent fibroblasts induces both mRNA and protein corresponding to the cellular thymidylate synthase (TS) gene, which encodes the enzyme that catalyzes the de novo synthesis of thymidylic acid.